Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 182

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update

Van Poznak, Catherine, Somerfield, Mark R., Barlow, William E., Biermann, J. Sybil, Bosserman, Linda D., Clemons, Mark J., Dhesy-Thind, Sukhbinder K., Dillmon, Melissa S., Eisen, Andrea, Frank, Elizabeth S., Jagsi, Reshma, Jimenez, Rachel, Theriault, Richard L., Vandenberg, Theodore A., Yee, Gary C., Moy, Beverly·2017·Journal of Clinical Oncology

Abstract

Purpose: To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-modifying agents (BMAs) in metastatic breast cancer. This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain. Methods: A joint ASCO-CCO Update Committee conducted targeted systematic literature reviews to identify relevant studies. Results: The Update Committee reviewed three phase III noninferiority trials of dosing intervals, one systematic review and meta-analysis of studies of de-escalation of BMAs, and two randomized trials of BMAs in control of pain secondary to bone metastases. Recommendations: Patients with breast cancer who have evidence of bone metastases should be treated with BMAs. Options include denosumab, 120 mg subcutaneously, every 4 weeks; pamidronate, 90 mg intravenously, every 3 to 4 weeks; or zoledronic acid, 4 mg intravenously every 12 weeks or every 3 to 4 weeks. The analgesic effects of BMAs are modest, and they should not be used alone for bone pain. The Update Committee recommends that the current standard of care for supportive care and pain management—analgesia, adjunct therapies, radiotherapy, surgery, systemic anticancer therapy, and referral to supportive care and pain management—be applied. Evidence is insufficient to support the use of one BMA over another. Additional information is available at www.asco.org/breast-cancer-guidelines and www.asco.org/guidelineswiki .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.75.4614

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 182

Metadata

Authors
Van Poznak, C., Somerfield, M. R., Barlow, W. E., Biermann, J. S., Bosserman, L. D., Clemons, M. J., Dhesy-Thind, S. K., Dillmon, M. S., Eisen, A., Frank, E. S., Jagsi, R., Jimenez, R., Theriault, R. L., Vandenberg, T. A., Yee, G. C., & Moy, B.
Venue
Journal of Clinical Oncology
Published
2017-12-10
Volume
35
Issue
35
Pages
3978-3986
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2765774285
Cited by
182
References
3
FWCI
7.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update. https://app.cochat.ai/papers/10.1200/jco.2017.75.4614
The paper
Van Poznak, C., Somerfield, M. R., Barlow, W. E., Biermann, J. S., Bosserman, L. D., Clemons, M. J., Dhesy-Thind, S. K., Dillmon, M. S., Eisen, A., Frank, E. S., Jagsi, R., Jimenez, R., Theriault, R. L., Vandenberg, T. A., Yee, G. C., & Moy, B. (2017). Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.75.4614

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.